Published in J Thorac Oncol on April 01, 2010
EGFR protein expression in non-small cell lung cancer predicts response to an EGFR tyrosine kinase inhibitor--a novel antibody for immunohistochemistry or AQUA technology. Clin Cancer Res (2011) 0.98
The pemetrexed-containing treatments in the non-small cell lung cancer is -/low thymidylate synthase expression better than +/high thymidylate synthase expression: a meta-analysis. BMC Cancer (2014) 0.95
Bcl-2 and β1-integrin predict survival in a tissue microarray of small cell lung cancer. Br J Cancer (2010) 0.92
New dilemmas in small-cell lung cancer TNM clinical staging. Onco Targets Ther (2013) 0.86
A functional approach reveals a genetic and physical interaction between ribonucleotide reductase and CHK1 in mammalian cells. PLoS One (2014) 0.79
The association of topoisomerase 2α expression with prognosis in surgically resected non-small cell lung cancer (NSCLC) patients. J Thorac Dis (2012) 0.78
Mining expression and prognosis of topoisomerase isoforms in non-small-cell lung cancer by using Oncomine and Kaplan-Meier plotter. PLoS One (2017) 0.75
Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A (2001) 24.34
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol (2008) 17.30
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med (2006) 10.48
DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med (2007) 8.28
Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med (2002) 8.04
A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol (1995) 3.79
Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol (2006) 3.71
Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst (2005) 3.62
Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J Pathol (2001) 3.09
Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res (2002) 2.96
An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res (2004) 2.94
RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol (2006) 2.60
Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res (2004) 2.54
Antigen retrieval immunohistochemistry: past, present, and future. J Histochem Cytochem (1997) 1.96
ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest (2005) 1.93
Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol (2007) 1.91
Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol (1996) 1.81
Correlation of in vitro drug-sensitivity testing results with response to chemotherapy and survival in extensive-stage small cell lung cancer: a prospective clinical trial. J Natl Cancer Inst (1990) 1.42
ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res (2005) 1.41
CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol (1992) 1.40
A novel dye exclusion method for testing in vitro chemosensitivity of human tumors. Cancer Res (1983) 1.38
Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res (2004) 1.32
Small cell lung cancer. Chest (2003) 1.31
Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. J Clin Oncol (2009) 1.30
Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J Thorac Oncol (2008) 1.26
Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America. Cancer (2002) 1.25
Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res (2000) 1.23
Thymidylate synthase: a critical target for cancer chemotherapy. Clin Colorectal Cancer (2002) 1.17
Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer. Cancer (2008) 1.15
Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer. J Clin Oncol (1999) 1.15
Treatment of extensive small cell lung cancer. Hematol Oncol Clin North Am (2004) 1.05
Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer. J Clin Oncol (2006) 0.96
The roles of DNA topoisomerase II during the cell cycle. Prog Cell Cycle Res (1996) 0.95
Survival of patients with limited-stage small cell lung cancer treated with individualized chemotherapy selected by in vitro drug sensitivity testing. Clin Cancer Res (1997) 0.93
Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. J Clin Oncol (1996) 0.93
Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival. Clin Cancer Res (2006) 0.93
New drugs for chemotherapy-naive patients with extensive-disease small cell lung cancer. Semin Oncol (2001) 0.90
Excision repair cross complementing-1 and topoisomerase IIalpha gene expression in small-cell lung cancer patients treated with platinum and etoposide: a retrospective study. J Thorac Oncol (2008) 0.88
Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: a Southwest Oncology Group phase II trial. Cancer J Sci Am (1999) 0.85
Using translational research to tailor the use of chemotherapy in the treatment of NSCLC. Lung Cancer (2005) 0.82
Derivation and characterization of monoclonal antibodies against human folypolyglutamate synthetase. Hybridoma (Larchmt) (2007) 0.82
Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer. Clin Lung Cancer (2006) 0.81
Enhanced expression of DNA topoisomerase II genes in human medulloblastoma and its possible association with etoposide sensitivity. J Neurooncol (2007) 0.79
Pharmacogenomics: a reality or still a promise? Lung Cancer (2006) 0.77
Topoisomerase 2alpha plays a pivotal role in the tumor biology of stage IV thymic neoplasia. Cancer (2007) 0.77
Derivation and characterization of a monoclonal antibody against human glycinamide ribonucleotide formyltransferase. Hybridoma (Larchmt) (2006) 0.77
Single-agent paclitaxel in the treatment of small cell lung cancer. Semin Oncol (1996) 0.77
New agents in the treatment of small-cell lung cancer: focus on gemcitabine. Clin Lung Cancer (2003) 0.76
DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med (2007) 8.28
Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res (2005) 5.04
Non-small cell lung cancer. J Natl Compr Canc Netw (2010) 3.93
Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006. Arch Intern Med (2008) 3.07
Racial diversity of actionable mutations in non-small cell lung cancer. J Thorac Oncol (2015) 2.80
Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst (2002) 2.77
Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung. Chest (2004) 2.73
Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res (2006) 2.68
Acidity generated by the tumor microenvironment drives local invasion. Cancer Res (2013) 2.63
Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res (2004) 2.54
Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol (2002) 2.51
MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res (2008) 2.33
Physician referral for fertility preservation in oncology patients: a national study of practice behaviors. J Clin Oncol (2009) 2.31
Incorporating genetic susceptibility feedback into a smoking cessation program for African-American smokers with low income. Cancer Epidemiol Biomarkers Prev (2002) 2.26
Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res (2005) 2.19
Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clin Cancer Res (2010) 2.19
Computed tomography response, but not positron emission tomography scan response, predicts survival after neoadjuvant chemotherapy for resectable non-small-cell lung cancer. J Clin Oncol (2008) 2.18
Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol (2009) 2.13
Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. J Biol Chem (2008) 2.07
Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol (2008) 1.97
RRM1-induced metastasis suppression through PTEN-regulated pathways. Oncogene (2003) 1.95
ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest (2005) 1.93
Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol (2007) 1.91
Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene (2003) 1.88
Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol (2010) 1.88
Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res (2005) 1.84
12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci Rep (2012) 1.81
A novel tool for the assessment of pain: validation in low back pain. PLoS Med (2009) 1.75
Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies. Nat Biotechnol (2013) 1.71
Non-small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw (2006) 1.68
Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase. Cancer Res (2006) 1.68
Suicide in patients with pancreatic cancer. Cancer (2010) 1.62
Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. J Clin Oncol (2008) 1.61
Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia. Clin Cancer Res (2006) 1.61
Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J Infect Dis (2002) 1.61
Establishment of two immortalized nasopharyngeal epithelial cell lines using SV40 large T and HPV16E6/E7 viral oncogenes. Biochim Biophys Acta (2002) 1.61
Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol (2013) 1.55
The human OGG1 DNA repair enzyme and its association with orolaryngeal cancer risk. Carcinogenesis (2002) 1.55
Relationship between tumor size and survival among patients with resection of multiple synchronous lung cancers. J Thorac Oncol (2010) 1.50
Neuronal IP3 3-kinase is an F-actin-bundling protein: role in dendritic targeting and regulation of spine morphology. Mol Biol Cell (2009) 1.48
Malignant pleural mesothelioma: a comprehensive review. Cancer Control (2006) 1.47
Proteomic contributions to personalized cancer care. Mol Cell Proteomics (2008) 1.46
Common cerebral networks associated with distinct deep brain stimulation targets for cluster headache. Cephalalgia (2013) 1.43
Corticosteroid Therapy Benefits Septic Mice With Adrenal Insufficiency But Harms Septic Mice Without Adrenal Insufficiency. Crit Care Med (2015) 1.39
Structure of a human inositol 1,4,5-trisphosphate 3-kinase: substrate binding reveals why it is not a phosphoinositide 3-kinase. Mol Cell (2004) 1.39
Pancreatic fistula rates after 462 distal pancreatectomies: staplers do not decrease fistula rates. J Gastrointest Surg (2008) 1.38
Agonist-induced regulation of mitochondrial and endoplasmic reticulum motility. Biochem J (2005) 1.37
Multiscale modelling of vascular tumour growth in 3D: the roles of domain size and boundary conditions. PLoS One (2011) 1.36
The guinea pig syndrome: improving clinical trial participation among thoracic patients. J Thorac Oncol (2007) 1.31
Paclitaxel affects cytosolic calcium signals by opening the mitochondrial permeability transition pore. J Biol Chem (2001) 1.29
JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling. Mol Cancer Ther (2011) 1.29
Lung cancer. Practice organization. Chest (2003) 1.27
ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood (2006) 1.27
A systematic review of quality of life associated with standard chemotherapy regimens for advanced non-small cell lung cancer. J Thorac Oncol (2007) 1.25
Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancer. J Clin Oncol (2004) 1.23
The feasibility of online genetic testing for lung cancer susceptibility: uptake of a web-based protocol and decision outcomes. Genet Med (2008) 1.23
Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung cancer. J Thorac Oncol (2011) 1.23
Responses to online GSTM1 genetic test results among smokers related to patients with lung cancer: a pilot study. Cancer Epidemiol Biomarkers Prev (2009) 1.22
Deregulation of IKBKE is associated with tumor progression, poor prognosis, and cisplatin resistance in ovarian cancer. Am J Pathol (2009) 1.20
Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci U S A (2013) 1.20
Identifying the main mosquito species in China based on DNA barcoding. PLoS One (2012) 1.19
Safety and pharmacokinetics of purified soy isoflavones: single-dose administration to postmenopausal women. Am J Clin Nutr (2002) 1.19
Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality. Int J Biochem Cell Biol (2007) 1.19
Determinants of metabotropic glutamate receptor-5-mediated Ca2+ and inositol 1,4,5-trisphosphate oscillation frequency. Receptor density versus agonist concentration. J Biol Chem (2002) 1.18
Persistent smoking after a diagnosis of lung cancer is associated with higher reported pain levels. J Pain (2009) 1.18
Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer. J Clin Oncol (2008) 1.17
Two motifs target Batten disease protein CLN3 to lysosomes in transfected nonneuronal and neuronal cells. Mol Biol Cell (2003) 1.16
Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer. Cancer (2008) 1.15
Regular aspirin use and lung cancer risk. BMC Cancer (2002) 1.15
The false discovery rate: a key concept in large-scale genetic studies. Cancer Control (2010) 1.14
Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer. Lung Cancer (2005) 1.12
Optimism bias leads to inconclusive results-an empirical study. J Clin Epidemiol (2010) 1.12
Continuous toxicity monitoring in phase II trials in oncology. Biometrics (2005) 1.12
Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells. PLoS One (2012) 1.12
Obtaining DNA from a geographically dispersed cohort of current and former smokers: use of mail-based mouthwash collection and monetary incentives. Nicotine Tob Res (2004) 1.11
ID1 facilitates the growth and metastasis of non-small cell lung cancer in response to nicotinic acetylcholine receptor and epidermal growth factor receptor signaling. Mol Cell Biol (2011) 1.11
Patient-provider communication and perspectives on smoking cessation and relapse in the oncology setting. Patient Educ Couns (2009) 1.11
DJ-1 promotes invasion and metastasis of pancreatic cancer cells by activating SRC/ERK/uPA. Carcinogenesis (2012) 1.10
Multi-institutional evaluation of deep brain stimulation targeting using probabilistic connectivity-based thalamic segmentation. J Neurosurg (2011) 1.07
Tripartite motif containing 28 (Trim28) can regulate cell proliferation by bridging HDAC1/E2F interactions. J Biol Chem (2012) 1.06
Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Cancer Res (2004) 1.06
A phase II study of RO4929097 in metastatic colorectal cancer. Eur J Cancer (2012) 1.05
Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Clin Cancer Res (2008) 1.04
ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis. Am J Pathol (2010) 1.04